Detalles de la búsqueda
1.
Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Endocr J
; 56(1): 149-56, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-18997444
2.
Comparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naïve Japanese patients with type 2 diabetes mellitus: A pilot study.
J Diabetes Investig
; 6(5): 560-6, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26417414
3.
Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide.
J Diabetes Investig
; 5(4): 400-9, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25411599
4.
Gut dysbiosis and detection of "live gut bacteria" in blood of Japanese patients with type 2 diabetes.
Diabetes Care
; 37(8): 2343-50, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24824547
5.
Morningness-eveningness questionnaire score correlates with glycated hemoglobin in middle-aged male workers with type 2 diabetes mellitus.
J Diabetes Investig
; 4(4): 376-81, 2013 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24843683
6.
Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study.
Endocr J
; 54(1): 163-6, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17185877
7.
Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus.
Endocr J
; 53(1): 67-72, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16543674
Resultados
1 -
7
de 7
1
Próxima >
>>